Acquisition-driven growth Infusionz was acquired in late 2022 by Bloomios Inc, signaling a potential shift in distribution, product lines, and sales channels. This presents opportunities to engage with the new parent company’s network and leverage expanded private-label capabilities.

Private-label appeal As part of Bloomios, Infusionz operates within a ecosystem known for white-label and private-label manufacturing of hemp-derived products, suggesting sales avenues in B2B partnerships, contract manufacturing, and co-branded product lines with retailers and brands.

Scale and reach gap Compared to larger peers, Infusionz’s mid-sized profile and revenue range indicate potential for scaled wholesale partnerships, distributor relationships, and entering new regional retailers to accelerate revenue without overextending operations.

Product diversification The focus on CBD, CBG, and CBN finished products opens cross-sell opportunities across different cannabinoid segments, enabling bundles, starter sets, and retailer assortments that can capture broader consumer demand.

Strategic partnerships With a Denver base and relatively modest payroll, Infusionz can target collaborations with mid-market distributors, spa and wellness brands, and nutraceuticals manufacturers seeking reliable finished-product supply, co-packaging, or private-label programs.